TMO - Danaher's guidance raise signals post-COVID lab recovery: Keybanc

Danaher Corporation ([[DHR]] +3.7%) has sustained its early gains following an upgrade to its Q1 2021 revenue guidance.The update highlights the company’s leadership in the global market for Covid-19 bioprocessing, noted Keybanc analyst Paul Knight with an outperform rating for the stock.The upgrade points to “industry color around the post-Covid-19 lab recovery,” Knight wrote with a price target at $280.00 per share for the stock implying ~19.2% upside to its previous close.Danaher peers, Hologic ([[HOLX]] +1.8%) and Thermo Fisher Scientific ([[TMO]] +1.4%) have also followed its gains to rise moderately in afternoon hours.Meanwhile, with a similar rating and a price target, Evercore ISI observes that the company’s base business has led to half of the revenue beat as implied by the upgrade.“The significant broad-based 1Q revenue beat fortifies our view that Danaher has one of the best and most durable portfolios addressing Covid-19,” wrote Cowen with an outperform rating on the

For further details see:

Danaher’s guidance raise signals post-COVID lab recovery: Keybanc